Education
About Us
Working with TipRanks
Follow Us
GNOM - ETF AI Analysis
Top Page
Global X Genomics & Biotechnology ETF (GNOM)
Rating:63Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past few months, indicating positive recent momentum.
Leading Genomics and Biotech Holdings
Several top positions, including companies like Moderna and other key biotech names, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Exposure to a High-Growth Theme
The fund is heavily focused on health care and genomics, giving investors targeted access to a specialized area with significant long-term growth potential.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so the ETF is very sensitive to downturns or regulatory changes affecting biotech and genomics companies.
Limited Geographic Diversification
With the vast majority of holdings in U.S. companies, the fund offers little international diversification.
Relatively High Expense Ratio
The ETF charges a higher fee than many broad-market index funds, which can modestly reduce net returns over time.
GNOM vs. SPDR S&P 500 ETF (SPY)
AUM49.83M
RegionGlobal
Expense Ratio0.50%
Beta1.19
IssuerGlobal X
Inception DateApr 05, 2019
Dividend Yield1.31%
Asset ClassEquity
Index TrackedSolactive Genomics Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,276
30 Day Avg. Volume10,444
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
65.62Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNOM Summary
GNOM is the Global X Genomics & Biotechnology ETF, which follows the Solactive Genomics Index and focuses on companies using DNA and gene science to improve healthcare. It mainly holds U.S. health care stocks involved in gene editing, genetic testing, and personalized medicine. Well-known holdings include Moderna and Illumina, both leaders in advanced biotech and genetic sequencing. Someone might invest in GNOM if they believe genomics could be a major long-term growth area and want a basket of these companies instead of picking single stocks. A key risk is that biotech shares can be very volatile and may rise or fall sharply.
How much will it cost me?The Global X Genomics & Biotechnology ETF (GNOM) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized sector like genomics and biotechnology, which requires more research and expertise. It’s designed to give investors exposure to cutting-edge companies in this innovative field.
What would affect this ETF?The GNOM ETF, focused on genomics and biotechnology, could benefit from advancements in gene editing and personalized medicine, as well as increased global healthcare spending and innovation. However, it may face challenges from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector. Its global exposure and top holdings in cutting-edge companies position it well for growth but also make it sensitive to changes in economic conditions and industry-specific risks.
GNOM Top 10 Holdings
GNOM is a pure-play bet on genomics, with almost everything riding on health-care names pushing the frontiers of gene editing, sequencing, and precision medicine. High-flyers like Moderna, Praxis, Guardant Health, and Illumina have been doing the heavy lifting lately, with rising share prices reflecting excitement around their pipelines and technology. On the other side, Arrowhead, BioMarin, and Vertex have been more mixed or lagging, occasionally putting sand in the ETF’s gears. With a global remit but a tight cluster of specialized biotech names, this fund is thematically bold and relatively concentrated.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines | 6.48% | $3.23M | $8.69B | 249.51% | 58 Neutral | |
| Moderna | 6.19% | $3.08M | $16.50B | 28.01% | 59 Neutral | |
| Arrowhead Pharmaceuticals | 5.90% | $2.94M | $8.94B | 219.90% | 57 Neutral | |
| Guardant Health | 5.42% | $2.70M | $13.56B | 117.89% | 61 Neutral | |
| Illumina | 4.59% | $2.29M | $17.86B | 16.53% | 71 Outperform | |
| BioMarin Pharmaceutical | 4.40% | $2.19M | $11.50B | -7.68% | 75 Outperform | |
| Vertex Pharmaceuticals | 4.25% | $2.12M | $124.70B | 7.07% | 78 Outperform | |
| Natera | 4.11% | $2.05M | $28.53B | 18.94% | 73 Outperform | |
| Avidity Biosciences | 3.99% | $1.99M | $11.28B | 125.53% | 62 Neutral | |
| Qiagen | 3.90% | $1.94M | $10.42B | 20.12% | 77 Outperform |
GNOM Technical Analysis
Neutral
―
Price Trends
47.04
Negative
44.54
Positive
39.23
Positive
Market Momentum
-0.41
Positive
42.23
Neutral
22.92
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 47.61, equal to the 50-day MA of 47.04, and equal to the 200-day MA of 39.23, indicating a neutral trend. The MACD of -0.41 indicates Positive momentum. The RSI at 42.23 is Neutral, neither overbought nor oversold. The STOCH value of 22.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GNOM.
GNOM Peer Comparison
Comparison Results
Performance Comparison
GNOM
Global X Genomics & Biotechnology ETF
45.81
6.30
15.95%
EVX
VanEck Environmental Services ETF
―
―
―
FDCF
Fidelity Disruptive Communications ETF
―
―
―
XAIX
Xtrackers Artificial Intelligence and Big Data ETF
―
―
―
FFND
Future Fund Active ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents